Acer Medical

Acer Medical Inc., a subsidiary of Acer Group, develops AI-powered medical imaging diagnostic software. Listed on Taiwan’s OTC market under ticker 6857.TWO, the company reports product deployments across more than 300 healthcare institutions in 13 countries.

Company Overview

Established in 2018, Acer Medical combines Acer Group’s technology expertise with clinical partnerships to develop Software as a Medical Device (SaMD) solutions. The company’s products use deep learning algorithms trained on images labeled by medical specialists, enabling healthcare providers to conduct rapid disease screening with accuracy comparable to specialists.

Originally named Acer Healthcare Inc., the company rebranded to Acer Medical Inc. to better reflect its focus on medical-grade AI solutions. The company maintains ISO 13485 certification for medical device quality management and has secured regulatory approvals from multiple international authorities including Taiwan FDA (TFDA), Thailand FDA, Indonesia Ministry of Health, Philippines FDA, Singapore HSA, and Malaysia MDA.

Core Products

VeriSee DR

Taiwan’s first AI ophthalmology Software as a Medical Device approved by TFDA. VeriSee DR analyzes fundus images to detect diabetic retinopathy with 93% screening accuracy. The software identifies four major DR lesions—microaneurysms, hemorrhages, soft exudates, and hard exudates—and provides referral recommendations within seconds.

VeriSee AMD

AI screening software for age-related macular degeneration targeting adults over 50 years. Clinical trials demonstrated 95% accuracy with 90% sensitivity and 96% specificity. The software analyzes fundus images to identify patients meeting AREDS level 3 or above criteria.

VeriOsteo OP

Taiwan’s first AI-powered bone mineral density screening software using chest X-ray analysis. Developed in collaboration with Taichung Veterans General Hospital, VeriOsteo OP calculates T-scores and predicts BMD abnormalities with approximately 90% accuracy, enabling osteoporosis risk assessment without specialized bone-scanning equipment.

ARC-1000

Non-mydriatic automated portable fundus camera designed to integrate with VeriSee software products. The device captures retinal images without pupil dilation, facilitating AI-assisted screening workflows in primary care settings.

VeriCompact APX-1

Portable X-ray system weighing 3.2 kg utilizing Carbon Nanotube (CNT) technology. Designed for medical imaging in remote environments with minimal radiation exposure.

Technology Platform

Acer Medical’s AI solutions run on Acer AI PCs powered by Intel Core Ultra processors, with algorithms optimized using Intel OpenVINO toolkit. This configuration reduces software startup time by 70%, analysis time per image by 90%, and memory usage by 90% compared to unoptimized implementations. All products operate without network connectivity, ensuring patient data privacy in clinical environments.

The company supports integration with major fundus camera brands including Topcon, Canon, Crystalvue, Nikon, and MiiS, and offers direct connectivity with hospital HIS and PACS systems.

Market Presence

In Taiwan, VeriSee products have achieved approximately 80% adoption rate among medical centers, with implementation at over 100 healthcare institutions including Taipei City Hospital’s six branches and National Taiwan University Hospital. The company expanded internationally beginning in 2022, with VeriSee DR now operational in over 30 hospitals across Thailand.

Acer Medical has accumulated 12+ medical device approvals across Taiwan and international markets. The company collaborates with pharmaceutical partners including Yung Shin Pharmaceutical to expand screening accessibility for diabetic patients.

Key Milestones

• 2018: Company founded as Acer Healthcare Inc.
• 2020: VeriSee DR becomes first AI ophthalmology SaMD approved by Taiwan FDA
• 2021: VeriSee DR receives Thailand FDA, Indonesia MoH approvals; company renamed to Acer Medical Inc.
• 2022: VeriSee AMD approved by Taiwan FDA; VeriSee DR approved by Philippines FDA
• 2023: VeriOsteo OP approved by Taiwan FDA
• 2024: VeriOsteo OP receives Taiwan Excellence Golden Award; expands to Singapore, Malaysia, Indonesia
• 2025: Company listed on Taiwan OTC (6857.TWO); VeriCompact APX-1 approved

Frequently Asked Questions

What products does Acer Medical offer?

Acer Medical develops AI-assisted medical imaging software including VeriSee DR for diabetic retinopathy, VeriSee AMD for macular degeneration, and VeriOsteo OP for bone density screening. The company also produces the ARC-1000 fundus camera and VeriCompact portable X-ray system.

Is Acer Medical publicly traded?

Yes, Acer Medical is listed on Taiwan’s OTC market under stock code 6857.TWO. The company is a subsidiary of Acer Inc., the global technology conglomerate listed on Taiwan Stock Exchange.

Where are Acer Medical products available?

Acer Medical products have received regulatory approvals and are commercially available in Taiwan, Thailand, Indonesia, Philippines, Malaysia, and Singapore. The company continues expanding into additional Southeast Asian markets.